Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adaptimmune Therapeutics PLC (ADAP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
05/12/2023 8-K Quarterly results
03/06/2023 8-K Quarterly results
11/08/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Adaptimmune Reports Q3 Financial Results and Business Update"
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update - Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients — - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started SURPASS trial — the first next-generation clinical trial with ADP-A2M4CD8 — - Will complete ADP-A2M10 trials by end of 2019 - - Announced that Adrian Rawcliffe will become Chief Executive Officer, and James Noble a Non-Executive Director on the Company's Board - - John Lunger promoted to new role of Chief Patient Supply Officer - - Rafael Amado, President of R&D, leaving the Company - - Initiated collaboration with Alpine Immune Sciences to develop next-generation SPEAR T-cells - - Continued support of clinical trial and com..."
05/06/2019 8-K Quarterly results
Docs: "Adaptimmune Reports First Quarter 2019 Financial Results - Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 -"
02/27/2019 8-K/A Quarterly results
02/27/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019 ~$26 million upon completion of transition of NY-ESO SPEAR T-cell program IND to GSK Closed registered direct offering with net proceeds of ~$100 million; guidance updated, funded to late 2020 Conference call to be held today at 8:00 a.m. EST"
08/02/2018 8-K Quarterly results
Docs: "Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update - Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells - - NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets - - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT -"
05/09/2018 8-K Quarterly results
Docs: "Adaptimmune Reports First Quarter 2018 Financial Results and Business Update - Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose - - Updated MRCLS response data will be presented in an oral presentation at ASCO - - Guidance confirmed, funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT -"
03/15/2018 8-K Quarterly results
Docs: "Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update - Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T-cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4 “basket” study at 100 million cell dose level - - Guidance confirmed: funded through to early 2020 - - Conference call to be held today at 8:00 a.m. EDT -",
"Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells - Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors -"
11/02/2017 8-K Quarterly results
Docs: "Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates — GlaxoSmithKline plc exercised its option to license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program — — Adaptimmune will receive up to $61 million from GSK over the course of the NY-ESO transition period, which extends funding through to early 2020 — — Clinical studies are ongoing with wholly owned assets across eight solid tumor indications"
08/03/2017 8-K Quarterly results
Docs: "Adaptimmune Reports Second Quarter 2017 Financial Results — A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 — — Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets across 12 different tumor indications — — On track for initial data from our wholly-owned assets in 2017 and 2018 — — NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting continue to indicate a favorable risk benefit profile in synovial sarcoma"
05/10/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/08/2016 8-K Form 8-K - Current report
05/12/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy